Neurocrine Biosciences: An Attractive Takeover Candidate with Potential >50% Upside.
FDA has accepted the New Drug Application (NDA) for Neurocrine Biosciences Inc (NBIX US) Valbenazine for the treatment of Tardive Dyskinesia (with...
421 Views
What Happens in Vegas...Goes to the White House (Hillary 2, Trump 1...Game Over!)
A Hillary victory would benefit Thai markets in terms of TIP market re-allocations and export strength, while hurting us on global stability....
207 Views
Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update
Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product...
393 Views
Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17
Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...
213 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
201 Views